Antibodies News and Research

RSS

Oxygen-rich lifesaving efforts pose risk for respiratory infections

Each year, thousands of premature infants battle to breathe. Thanks to life-saving interventions developed in the past couple decades - steroids given to their mothers to stall pre-term labor, mechanical ventilation, air enriched with extra oxygen, and surfactant, a crucial wetting agent that makes breathing less work - most of these newborns survive with enough lung function to grow and go home.

11 Jun 2008

Scientists identify a key regulator of DNA mutations

As a general rule, your DNA is not something you want rearranged. But there are exceptions - especially when it comes to fighting infections. Since the number of microbes in the world far surpasses the amount of human DNA dedicated to combat them, specialized cells in the immune system have adopted an ingenious, if potentially disastrous, strategy for making antibodies. These cells, called B lymphocytes, intentionally mutate their own DNA to ward off invaders they have never seen before.

9 Jun 2008

Role of breastfeeding in preventing infant death, HIV infection in developing countries

In many poor countries, mothers with HIV face a stark choice: to nurse their infants, and risk passing on HIV through their breast milk - or to formula feed, and deprive their infants of much of the natural immunity needed to protect against fatal diseases of early infancy. Now, two studies supported by the National Institutes of Health offer insights into preventing early death and HIV infection among breastfeeding infants of mothers with HIV in these countries.

5 Jun 2008

Bird flu hits the UK and the U.S.

Tests currently being conducted will determine just how virulent the H7 strain is and in the meantime a temporary inner control zone of 3km has been set up around the farm along with a 10km outer zone.

5 Jun 2008

Arana and Greenovation in anti-cancer co-development deal

Arana Therapeutics Limited and Germany-based greenovation Biotech GmbH have entered into a collaborative agreement to develop next generation anti-cancer antibodies.

2 Jun 2008

New breast cancer drug combo shrinks aggressive tumours

An international trial of a new breast cancer drug has shown the drug is able to shrink tumours caused by one of the most aggressive forms of the disease.

2 Jun 2008

Why do Finnish children have type 1 diabetes and allergic symptoms approximately five times more often than children in Russian Karelia?

High living standards and the life style connected to them seem to promote the development of autoimmune diseases and allergic symptoms. This has lead to the assumption that the immune system begins to overreact to the organism's own structures or to exogenous non-infectious proteins, i.e. allergens, when it does not have to work hard enough to protect the individual from infections.

28 May 2008

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer

A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.

27 May 2008

Scientists back the use of maize as an efficient 'factory' for protein-based pharmaceutical products

Scientists from the Universidad de Lleida (University of Lleida) have published a study confirming that maize seeds are an effective and sure platform within molecular agriculture to alleviate diseases. Over the next few years AIDS could be one of the first diseases to benefit from these results, although regulations for this technology are being developed at the same time as research is being undertaken.

25 May 2008

Discovery provides hope for patients with pancreatic cancer

This week researchers in the Oregon Health & Science University (OHSU) Oregon Stem Cell Center and the OHSU Digestive Health Center are shining a new ray of hope on patients with pancreatic cancer. They've developed new reagents, or antibodies, that can recognize this often lethal disease. This important discovery may one day lead to earlier detection and treatment.

22 May 2008

An alternative strategy for HIV vaccine research

Today, Advanced BioScience Laboratories, Inc. (ABL) and the University of Massachusetts Medical School (UMMS) report that their unique HIV vaccine formulation was effective in eliciting strong and balanced immune responses in healthy human volunteers.

22 May 2008

Discovery of a molecular scaffold that guides connections between brain cells

Brain cells known as neurons process information by joining into complex networks, transmitting signals to each other across junctions called synapses. But "neurons don't just connect to other neurons," emphasizes Z. Josh Huang, Ph.D., "in a lot of cases, they connect to very specific partners, at particular spots."

21 May 2008

Having a cat may protect children from developing asthma

A study released by researchers at the Columbia Center for Children's Environmental Health (CCCEH) at Columbia University's Mailman School of Public Health, shows that cat ownership may have a protective effect against the development of asthma symptoms in young children at age five.

20 May 2008

NIAID to advance B-cell approach to HIV vaccines

To advance underdeveloped approaches to designing a preventive HIV vaccine, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is launching a new program to foster the study of B cells, immune cells that can produce antibodies with the capacity to neutralize HIV.

20 May 2008

Counting immune cells on a 'protein printboard'

In order to monitor how far an HIV infection has progressed, the number of immune cells - lymphocytes - must be counted. Researchers at the University of Twente have developed a method that neatly arranges the antibodies that bind to these immune cells on a 'molecular printboard'. The researchers are publishing this key step in the road towards antibody-based sensors in the Journal of the American Chemical Society (JACS).

20 May 2008

Chemically modified protein may help people with hard-to-treat hemophilia

Pathologists at The University of Texas Health Science Center at Houston have developed a chemically modified protein that may help people with a hard-to-treat form of a genetic bleeding disorder known as Hemophilia A. The discovery and the results of pre-clinical tests appear in the May 2 issue of the Journal of Biological Chemistry.

19 May 2008

Researchers discover 'reservoir' that allows HIV to remain infectious despite treatment

Researchers at Brigham Young University and the Johns Hopkins School of Medicine have discovered a human cell "reservoir," called follicular dendritic cells, that allows HIV to stay in an infectious state and not respond to antiretroviral drugs, the Deseret Morning News reports.

19 May 2008

Schering-Plough extends antibody aliance with MorphoSys

MorphoSys AG announced today that Schering-Plough Corporation has decided to extend the current collaboration between the two companies for one year.

19 May 2008

New theory suggests how hepatitis C may cause rare immune disease

Of the hepatitis alphabet, the C variant may be the nastiest. In 1990, researchers observed that most patients with hepatitis C also develop a rare autoimmune disease called mixed cryoglobulinemia, a condition that frequently leads to cancer, arthritis or both.

10 May 2008

PolyMedix receives clearance to initiate phase I clinical study of novel systemic antibiotic compound

PolyMedix, Inc. has received a notice of no objection from Health Canada for the Company's Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of human clinical studies in Canada. PMX-30063 is the first defensin mimetic antibiotic compound cleared to enter human clinical trials for systemic use, representing an entirely new class of antibiotic drugs.

9 May 2008

Antibodies News and Research

Oxygen-rich lifesaving efforts pose risk for respiratory infections

Scientists identify a key regulator of DNA mutations

Role of breastfeeding in preventing infant death, HIV infection in developing countries

Bird flu hits the UK and the U.S.

Arana and Greenovation in anti-cancer co-development deal

New breast cancer drug combo shrinks aggressive tumours

Why do Finnish children have type 1 diabetes and allergic symptoms approximately five times more often than children in Russian Karelia?

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer

Scientists back the use of maize as an efficient 'factory' for protein-based pharmaceutical products

Discovery provides hope for patients with pancreatic cancer

An alternative strategy for HIV vaccine research

Discovery of a molecular scaffold that guides connections between brain cells

Having a cat may protect children from developing asthma

NIAID to advance B-cell approach to HIV vaccines

Counting immune cells on a 'protein printboard'

Chemically modified protein may help people with hard-to-treat hemophilia

Researchers discover 'reservoir' that allows HIV to remain infectious despite treatment

Schering-Plough extends antibody aliance with MorphoSys

New theory suggests how hepatitis C may cause rare immune disease

PolyMedix receives clearance to initiate phase I clinical study of novel systemic antibiotic compound

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery